Malin Corporation, the Dublin-based life sciences investment firm, saw its share soar 37 per cent in early trading on Tuesday after the company behind its most valuable investment agreed to be taken over by Swiss pharmaceuticals giant Roche. Photograph: Philipp Schmidli/Bloomberg
Shareholders are set to receive $9 per share at the closing of the deal early next year, and much as $4 per share subject to Poseida, which has a number of treatments in clinical trials as it focuses on the fields of oncology, immunology, and neurology. The now-abandoned €45 million buyback was planned as a way of handing out proceeds from Malin’s sale of its stake in a company called CG Oncology.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: